Project TitleMethod for High Yields of Extracellular Nanoparticles (15035)
Track Code15035
Short DescriptionNone

Method for High Yields of Extracellular Nanoparticles (15035)



Features and Benefits Summary

  • This study demonstrates for the first time that HG-nanoparticles are excellent candidates for use as a diagnostic and therapeutic delivery agent.

  • HG-nanoparticles can transport chemotherapeutic agents to different types of cells without causing cytotoxicity or an immune reaction.

 *This Technology is available for licensing, further development, or industrial partnering*


Market Opportunities

The recent increase of extracellular microvesicles (EVs) research has strongly emphasized the application of these vesicles as diagnostic and treatment-monitoring tools. By utilizing the most abundant EVs circulating in the body, HG-nanoparticles offer the best resource for such applications. Exosomes, due to the proteins, bioactive lipids, and genetic information they carry, alter the phenotype and function of recipient cells, suggesting that they serve numerous biological processes and their heterogeneity makes it challenging to isolate and purify for analytical approaches. HG-nanoparticles are more homogenous (all around 8-12 nm in size) and can be readily detected in blood and cell culture supernatants without further complicated in vitro manipulations. Therefore, HG-nanoparticles offer a better source for disease diagnosis than EVs, are non-invasive, and can be used as a screening tool to detect stages of certain types of cancers.



Exosomal RNAs have recently attracted enormous attention in the medical field due to their potential application in diagnostics, prognostics, and tumor therapy. However, when using current standard extraction methods, exosomes are produced in extremely low yields, making exploring their applications thus far challenging. This study has discovered a prominent, uniform subpopulation of extracellular nanovesicles (NVs) in the mammalian circulatory system and identified a method to extract and filter them in unprecedent high yields: 50-fold higher than current standard. Dubbed HG-(Huang-Ge, after inventor) nanoparticles, they are enriched with lipids, RNAs, and proteins.

Through this study, HG-nanoparticles’ RNAs have been shown to be excellent candidates for use as diagnostic and prognostic potential markers, as well as a therapeutic delivery vector for chemotherapeutics, siRNAs, and DNA expression vectors. An additional benefit, HG-nanoparticles do not induce a cytotoxic effect or illicit an immune response. The study also explored in vivo the targeting specificity of HG-nanoparticles by co-delivering them with folic acid as a ligand. In cells that expressed folate receptors, a significantly higher targeting efficiency was produced and established HG-nanoparticles’ potential as targeted delivery vehicles.

Figure 1: Liver micro-tumors from mice showing the relative abundance and uniformity of HG-NVs compared to exosomes.


Technology Status

  • IP Status: Provisional 62/318,588
  • Development Status: Ready for clinical translation.



  • Dr. Huang-Ge Zhang

  • Dr. Qilong Wang

TagsDrug Screening & Discovery, drug delivery, diagnostics, therapeutics
Posted DateMar 10, 2017 4:00 PM


File Name Description
15035 Figure 1.png None Download